Benefits
Bone Health and Fracture Prevention
Vitamin D is essential for calcium absorption and bone mineralization, helping to maintain strong bones and prevent conditions such as rickets in children and osteomalacia in adults. Supplementation, particularly when combined with calcium, modestly increases bone mineral density and reduces fracture risk in older adults and those with low baseline vitamin D levels. The benefits for bone health are most pronounced in individuals who are deficient or at high risk of deficiency
Immune System Support and Autoimmune Disease Prevention
Vitamin D plays a role in modulating immune responses, reducing inflammation, and potentially lowering the risk of autoimmune diseases. The VITAL study found that daily supplementation (2,000 IU) led to a 22% reduction in the incidence of autoimmune diseases, such as rheumatoid arthritis and psoriasis, over five years—even among those with sufficient baseline vitamin D. Adequate vitamin D status is associated with improved resistance to infections and may reduce the risk of respiratory illnesses, including severe flu and COVID-19
Chronic Disease and Mortality Risk Reduction
Higher vitamin D levels are linked to lower risks of major diseases and mortality, including cardiovascular disease, diabetes, and some cancers. Meta-analyses suggest vitamin D supplementation may modestly decrease cancer mortality and all-cause mortality, especially with vitamin D3. Some studies indicate that supplementation can modestly delay age-related bone loss and progression to type 2 diabetes in deficient individuals
Mechanism of action
Metabolic Activation
Vitamin D (either D2 or D3) is first hydroxylated in the liver to form 25-hydroxyvitamin D [25(OH)D], the main circulating form. A second hydroxylation occurs primarily in the kidney, producing the active form, 1,25-dihydroxyvitamin D [1,25(OH)₂D, also called calcitriol]. These steps are catalyzed by cytochrome P450 enzymes (CYPs), such as CYP2R1 in the liver and CYP27B1 in the kidney
Genomic Actions
Calcitriol binds to the vitamin D receptor (VDR), a nuclear transcription factor present in many cell types. The VDR-calcitriol complex forms a heterodimer with the retinoid X receptor (RXR). This complex binds to vitamin D response elements (VDREs) in the DNA, regulating the transcription of hundreds of genes. These genes are involved in calcium and phosphate homeostasis, cell proliferation, differentiation, and immune function
Non-Genomic Actions
Some effects of vitamin D are too rapid to be explained by gene transcription, such as rapid calcium uptake in cells. These may be mediated by membrane-associated receptors and signaling pathways, including PDIA3
Clinical trials
Multiple RCTs and meta-analyses including 2019 JAMA (n=53,537) examining vitamin D supplementation for fracture prevention.
Pooled across large RCTs.
MIXED RESULTS: vitamin D ALONE has NOT consistently reduced fracture risk in vitamin D-replete populations. VITD ALONE NEGATIVE in WHI, RECORD trials. CALCIUM + VITAMIN D combinations: modest fracture reduction in DEFICIENT populations and institutionalized elderly. The 'vitamin D for bone health' marketing oversimplifies — benefit is largely confined to deficient populations.
2017 meta-analysis in BMJ (25 trials, n=11,321) of vitamin D supplementation (800-4,000 IU daily) for acute respiratory infection prevention. (Martineau et al. 2017, BMJ)
Pooled across 25 RCTs.
Vitamin D modestly reduced ARI risk (~12% relative reduction); larger benefit in those with severe baseline deficiency (<25 nmol/L) — ~70% reduction. Daily/weekly dosing more effective than bolus dosing. Note: subsequent VITAL and similar trials in vitamin D-replete populations have been more equivocal.
2014 meta-analysis in Age and Ageing (30 trials, n=5,615) of vitamin D supplementation (800-1,000 IU daily) for muscle function/falls.
Pooled across 30 elderly RCTs.
Vitamin D modestly reduced falls in elderly (most benefit in deficient and institutionalized populations). Note: USPSTF 2018 recommended AGAINST vitamin D for fall prevention in community-dwelling adults (insufficient evidence outside deficient populations).
2020 meta-analysis in Nutrients (41 trials, n=25,871) of vitamin D supplementation (1,000-4,000 IU daily) for CV outcomes.
Pooled across 41 CV RCTs.
PRIMARY ENDPOINT NEGATIVE: vitamin D did NOT reduce CV events. Major large RCTs (VITAL, ViDA, D-Health) all NEGATIVE for CV prevention. Important rigorous negative literature.
2018 meta-analysis in J Affective Disorders (31 trials, n=16,287) of vitamin D supplementation for depression.
Pooled across 31 depression RCTs.
Modest signal for vitamin D reducing depressive symptoms in DEFICIENT populations; minimal effect in non-deficient. SAD-specific evidence weaker than commonly believed.
2019 randomized trial (VITAL, n=25,871) of high-dose vitamin D (2,000 IU daily) over 5 years. (Manson et al. 2019, NEJM)
25,871 adults. Long-term.
PRIMARY ENDPOINT NEGATIVE: vitamin D did NOT reduce overall cancer incidence vs placebo. Modest signal for cancer mortality reduction in long-term follow-up. CARDIOVASCULAR primary endpoint also NEGATIVE. Largest definitive vitamin D RCT — substantially deflated enthusiasm for chemoprevention.
2021 RCT (n=240) in J Clin Endocrinol Metab of high-dose vitamin D (200,000 IU bolus) for COVID-19 outcomes.
240 COVID-19 patients.
Mixed signals; large bolus dosing may be ineffective. Subsequent CORONAVIT and similar trials in COVID generally NEGATIVE for definitive treatment role. Maintaining adequate vitamin D status is generally health-supportive but not COVID-specific therapy.